TABLE 1.

Aspergillus fumigatus strains used in this study and their in vitro antifungal susceptibility profiles against three triazoles according to the Etest method^a

Strain(s)	Parent	Genotypeb	MICs (μg/ml)c			Source
			VRC	ITC	POS
NIID0345	clinical isolate		1.0	>8	0.5	Current study
NIID0345-mut1-2	NIID0345	mut1 mut2 cyp51A hph	1.5	>8	0.75	Current study
NIID0345-S138G	NIID0345	mut1 S138G mut2 cyp51A hph	0.5	1.0	0.25	Current study
NIID0345-K248N	NIID0345	mut1 K248N mut2 cyp51A hph	2	>8	0.5	Current study
NIID0345-S138G-K248N	NIID0345	mut1 mut2 cyp51A hph	0.5	1.0	0.25	Current study
AfS35	D141	akuAΔloxP	0.094	0.5	0.125	Fungal Genetics Stock Center
AfS35-mut1-2	AfS35	mut1 mut2 cyp51A hph	0.125	0.5	0.125	Current study
AfS35-G138S	AfS35	mut1 G138S mut2 cyp51A hph	0.38	1.5	0.19	Current study

^aSee Fig. 1 and 3.

^bmut1 and mut2 are silent mutations for Cas9-nuclease resistance.

^cVRC, voriconazole; ITC, itraconazole; POS, posaconazole.